FDA Panel Considers Easing Peptide Restrictions Amid Calls for Greater Access to Life Saving Treatments The US Food and Drug Administration is deliberating on proposals to ease restrictions on peptide based medications.
This move could have significant implications for medical innovation and patient access to life saving treatments.
At the heart of this debate are concerns over the regulatory framework governing peptides, which has been at the center of a contentious discussion in recent years.